Illumina Inc., a global leader in DNA sequencing and array-based technologies, has announced the launch of a new generation of its distributed liquid biopsy assay for genomic profiling. The TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay designed for noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. This assay is particularly useful when tissue testing is not available or as a complement to tissue-based testing.
The TSO 500 ctDNA v2 offers key improvements, including a faster sample-to-answer turnaround time of less than four days, higher sensitivity with lower cell-free DNA (cfDNA) input requirements, and a more streamlined workflow. This enhanced workflow will be further optimized with automation in the first half of 2024. Kevin Keegan, general manager of Oncology at Illumina, highlighted the increasing adoption of liquid-biopsy-based CGP by leading cancer centers and the potential of the TSO 500 ctDNA v2 assay to provide deeper insights for cancer research.